Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 61 to 63 of 63 entries
Sorted by: Best Match Show Resources per page
Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical therapy in heart failure with reduced ejection fraction.

European journal of heart failure

Seferović PM, Polovina M, Adlbrecht C, Bělohlávek J, Chioncel O, Goncalvesová E, Milinković I, Grupper A, Halmosi R, Kamzola G, Koskinas KC, Lopatin Y, Parkhomenko A, Põder P, Ristić AD, Šakalytė G, Trbušić M, Tundybayeva M, Vrtovec B, Yotov YT, Miličić D, Ponikowski P, Metra M, Rosano G, Coats AJS.
PMID: 34755422
Eur J Heart Fail. 2021 Dec;23(12):1999-2007. doi: 10.1002/ejhf.2378. Epub 2021 Dec 13.

Guideline-directed medical therapy (GDMT) has the potential to reduce the risks of mortality and hospitalisation in patients with heart failure (HF) with reduced ejection fraction (HFrEF). However, real-world data indicate that many patients with HFrEF do not receive optimised...

Cite
Seferović PM, Polovina M, Adlbrecht C, et al. Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. Eur J Heart Fail. 2021;23(12):1999-2007doi: 10.1002/ejhf.2378.
Seferović, P. M., Polovina, M., Adlbrecht, C., Bělohlávek, J., Chioncel, O., Goncalvesová, E., Milinković, I., Grupper, A., Halmosi, R., Kamzola, G., Koskinas, K. C., Lopatin, Y., Parkhomenko, A., Põder, P., Ristić, A. D., Šakalytė, G., Trbušić, M., Tundybayeva, M., Vrtovec, B., Yotov, Y. T., Miličić, D., Ponikowski, P., Metra, M., Rosano, G., & Coats, A. J. S. (2021). Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. European journal of heart failure, 23(12), 1999-2007. https://doi.org/10.1002/ejhf.2378
Seferović, Petar M, et al. "Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical therapy in heart failure with reduced ejection fraction." European journal of heart failure vol. 23,12 (2021): 1999-2007. doi: https://doi.org/10.1002/ejhf.2378
Seferović PM, Polovina M, Adlbrecht C, Bělohlávek J, Chioncel O, Goncalvesová E, Milinković I, Grupper A, Halmosi R, Kamzola G, Koskinas KC, Lopatin Y, Parkhomenko A, Põder P, Ristić AD, Šakalytė G, Trbušić M, Tundybayeva M, Vrtovec B, Yotov YT, Miličić D, Ponikowski P, Metra M, Rosano G, Coats AJS. Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. Eur J Heart Fail. 2021 Dec;23(12):1999-2007. doi: 10.1002/ejhf.2378. Epub 2021 Dec 13. PMID: 34755422.
Copy Download .nbib Format: NLM
Coupling between structural properties and charge transport in nano-crystalline and amorphous graphitic carbon films, deposited by electron-beam evaporation.

Nanotechnology

Brus VV, Ilashchuk MI, Orletskyi IG, Solovan MM, Parkhomenko GP, Babichuk IS, Schopp N, Andrushchak GO, Mostovyi AI, Maryanchuk PD.
PMID: 32924974
Nanotechnology. 2020 Dec 11;31(50):505706. doi: 10.1088/1361-6528/abb5d4.

Nano-crystalline and amorphous films of graphitized carbon were deposited by electron-beam evaporation of bulk graphite. Structural properties and the size of graphite nanoclusters (L ≈ 1.2-5 nm) in the films were determined from the analysis of their Raman spectra....

Cite
Brus VV, Ilashchuk MI, Orletskyi IG, et al. Coupling between structural properties and charge transport in nano-crystalline and amorphous graphitic carbon films, deposited by electron-beam evaporation. Nanotechnology. 2020;31(50):505706doi: 10.1088/1361-6528/abb5d4.
Brus, V. V., Ilashchuk, M. I., Orletskyi, I. G., Solovan, M. M., Parkhomenko, G. P., Babichuk, I. S., Schopp, N., Andrushchak, G. O., Mostovyi, A. I., & Maryanchuk, P. D. (2020). Coupling between structural properties and charge transport in nano-crystalline and amorphous graphitic carbon films, deposited by electron-beam evaporation. Nanotechnology, 31(50), 505706. https://doi.org/10.1088/1361-6528/abb5d4
Brus, V V, et al. "Coupling between structural properties and charge transport in nano-crystalline and amorphous graphitic carbon films, deposited by electron-beam evaporation." Nanotechnology vol. 31,50 (2020): 505706. doi: https://doi.org/10.1088/1361-6528/abb5d4
Brus VV, Ilashchuk MI, Orletskyi IG, Solovan MM, Parkhomenko GP, Babichuk IS, Schopp N, Andrushchak GO, Mostovyi AI, Maryanchuk PD. Coupling between structural properties and charge transport in nano-crystalline and amorphous graphitic carbon films, deposited by electron-beam evaporation. Nanotechnology. 2020 Dec 11;31(50):505706. doi: 10.1088/1361-6528/abb5d4. PMID: 32924974.
Copy Download .nbib Format: NLM
Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial.

European journal of preventive cardiology

Diaz R, Li QH, Bhatt DL, Bittner VA, Baccara-Dinet MT, Goodman SG, Jukema JW, Kimura T, Parkhomenko A, Pordy R, Reiner Ž, Roe MT, Szarek M, Tse HF, White HD, Zahger D, Zeiher AM, Schwartz GG, Steg PG.
PMID: 33755145
Eur J Prev Cardiol. 2021 Mar 23;28(1):33-43. doi: 10.1177/2047487320941987. Epub 2020 Jul 27.

AIMS: Statins are pivotal to the secondary prevention of major adverse cardiovascular events, but some patients are statin-intolerant. We examined the effects of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab on the risk of major adverse cardiovascular...

Cite
Diaz R, Li QH, Bhatt DL, et al. Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. Eur J Prev Cardiol. 2020;28(1):33-43doi: 10.1177/2047487320941987.
Diaz, R., Li, Q. H., Bhatt, D. L., Bittner, V. A., Baccara-Dinet, M. T., Goodman, S. G., Jukema, J. W., Kimura, T., Parkhomenko, A., Pordy, R., Reiner, �. �., Roe, M. T., Szarek, M., Tse, H. F., White, H. D., Zahger, D., Zeiher, A. M., Schwartz, G. G., Steg, P. G. (2021). Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. European journal of preventive cardiology, 28(1), 33-43. https://doi.org/10.1177/2047487320941987
Diaz, Rafael, et al. "Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial." European journal of preventive cardiology vol. 28,1 (2021): 33-43. doi: https://doi.org/10.1177/2047487320941987
Diaz R, Li QH, Bhatt DL, Bittner VA, Baccara-Dinet MT, Goodman SG, Jukema JW, Kimura T, Parkhomenko A, Pordy R, Reiner Ž, Roe MT, Szarek M, Tse HF, White HD, Zahger D, Zeiher AM, Schwartz GG, Steg PG. Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. Eur J Prev Cardiol. 2021 Mar 23;28(1):33-43. doi: 10.1177/2047487320941987. Epub 2020 Jul 27. PMID: 33755145.
Copy Download .nbib Format: NLM
Showing 61 to 63 of 63 entries